Mechanism of action
Tirzepatide is a single 39-amino-acid peptide, built on the GIP sequence, that activates two gut hormone receptors: GIP and GLP-1. Like other GLP-1 receptor agonists, it raises insulin when blood sugar is high, slows stomach emptying and reduces appetite. A fatty side chain lets it bind to albumin in the blood, so one injection lasts a week.
Approvals
The FDA approved tirzepatide as Mounjaro on May 13, 2022, as the first dual GIP and GLP-1 receptor agonist for type 2 diabetes. It was approved as Zepbound for chronic weight management on November 8, 2023, for adults with obesity, or with overweight and at least one weight-related condition. On December 20, 2024, Zepbound became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity.
Tirzepatide comes in doses from 2.5 mg to 15 mg. The label raises the dose step by step over several weeks (see titration).
Clinical trials
The weight-management approval rests on the SURMOUNT trials. In SURMOUNT-1, adults without diabetes on tirzepatide 15 mg lost 20.9% of their body weight on average after 72 weeks, vs. 3.1% on placebo.
In the one head-to-head trial, SURMOUNT-5, people on tirzepatide lost 20.2% and people on semaglutide lost 13.7% after 72 weeks (treatment-regimen estimand).
When the FDA approved Zepbound, it noted that the two main weight trials included 2,519 people on tirzepatide and 958 on placebo. The sleep apnea approval was based on SURMOUNT-OSA, which enrolled adults with obesity and moderate to severe sleep apnea. In SURMOUNT-MAINTAIN, published in The Lancet in 2026, adults who had lost weight on the highest tolerated dose were assigned to stay on it, lower to 5 mg or switch to placebo, to study how weight is kept off.
Side effects and availability
The most common side effects of tirzepatide are nausea, diarrhea, vomiting, constipation, stomach pain and injection site reactions. The label has a boxed warning about thyroid C-cell tumors seen in rodents.
Brand-name tirzepatide is sold by prescription in single-dose pens and vials, multi-dose vials and multi-dose KwikPens, for both Mounjaro and Zepbound. Compounded tirzepatide is prepared by state-licensed pharmacies for an individual prescription and is not an FDA-approved product. Online programs are compared on our compounded tirzepatide page.
Timeline
- 2022-05-13Mounjaro approved for type 2 diabetes
- 2023-11-08Zepbound approved for chronic weight management
- 2024-12-20Zepbound approved for moderate to severe obstructive sleep apnea in adults with obesity
- 2025-12Mounjaro label extended to children aged 10 and older with type 2 diabetes
- 2026-08-28Mounjaro approved to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk (SURPASS-CVOT)
See also
References
- Mounjaro prescribing information, DailyMed. dailymed.nlm.nih.gov
- FDA approves new medication for chronic weight management (FDA, November 8, 2023). fda.gov
- Zepbound prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
- Aronne et al., NEJM 2025 (SURMOUNT-5). pubmed.ncbi.nlm.nih.gov
- Horn et al., Lancet 2026 (SURMOUNT-MAINTAIN). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.